A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä

Altered Glucagon Response to Oral Glucose in Individuals at Different Stages of Type 1 Diabetes Development




TekijätKontola, Helena; Crisóstomo, Luís; Löyttyniemi, Eliisa; Koskenniemi, Jaakko J.; Veijola, Riitta; Toppari, Jorma; Kero, Jukka

Kustantaja Oxford University Press

Julkaisuvuosi2025

Lehti:Journal of Clinical Endocrinology and Metabolism

Artikkelin numerodgaf601

ISSN0021-972X

eISSN1945-7197

DOIhttps://doi.org/10.1210/clinem/dgaf601

Verkko-osoitehttps://doi.org/10.1210/clinem/dgaf601

Rinnakkaistallenteen osoitehttps://research.utu.fi/converis/portal/detail/Publication/505183580


Tiivistelmä

Context

Autoimmune destruction of beta cells and their functional decline precedes the clinical onset of type 1 diabetes. However, altered alpha-cell function and hyperglucagonemia may contribute to the development of hyperglycemia and ketoacidosis at onset.

Objective

In this cross-sectional study, we analyzed glucagon concentrations during an oral glucose tolerance test (OGTT) in individuals at early stages of type 1 diabetes to understand the role of alpha-cell function in the disease process.

Methods

We recruited 47 participants, aged 4–25 years, from the Finnish Diabetes Prediction and Prevention (DIPP) study, categorized them into the following groups: islet autoantibody (IAb) negative, single IAb positive, and stages 1-3 of type 1 diabetes. Glucagon levels were measured during a six-point OGTT using a conventional radioimmunoassay, alongside insulin, C-peptide, glucose and glucagon-like peptide-1 (GLP-1).

Results

Fasting plasma glucagon levels increased with disease progression. The longitudinal patterns of glucagon concentrations during the OGTT differed significantly between groups, with a paradoxical 15-minute glucagon increase observed only in individuals at early stage 3 of type 1 diabetes.

Conclusion

These findings highlight the need for prospective studies to further elucidate the role of alpha-cells in disease progression and support testing pharmacotherapies aimed at improving both alpha- and beta-cell functions during disease development.


Ladattava julkaisu

This is an electronic reprint of the original article.
This reprint may differ from the original in pagination and typographic detail. Please cite the original version.




Julkaisussa olevat rahoitustiedot
This study was supported by grants from Sigrid Juselius Foundation Finland (JK, grant number 1062/Kero), Pediatric Research Foundation, Finland (JK, HK grant numbers 190001 and 210212, JT), Turku University Hospital Special Governmental Funding (JK, HK, JT grant numbers 13527, 210212, 13420) and TYKS foundation grant (HK), Turku University Foundation, Finland (HK) and The Alma and K.A. Snellmann Foundation, Oulu, Finland (HK), JDFR International, Kyllikki and Uolevi Lehikoinen’s foundation (J.J.K) and Foundation for Pediatric Research, and Finnish Cultural Foundation (J.J.K)


Last updated on 2025-06-11 at 14:26